Clinical and Technical Considerations for Brain PET Imaging for Dementia.

Abstract

The number of cases of dementia has dramatically increased over the last decade. Imaging of the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia have vastly improved. In recent years, the U.S. Food and Drug Administration has approved 3 PET radiopharmaceuticals for detecting amyloid in brain, and tau PET radiopharmaceuticals are being investigated in clinical trials for use in dementia imaging. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.

• Authors: Shelley N Acuff, Sulantha Mathotaarachchi, Katherine Zukotynski, Dustin Osborne, Rathan Subramaniam, Alzheimer’s Disease Neuroimaging Initiative
• Journal: Journal of nuclear medicine technology (J Nucl Med Technol) Vol. 48 Issue 1 Pg. 5-8 (Mar 2020) ISSN: 1535-5675 [Electronic] United States
• PMID: 31182663 (Publication Type: Journal Article, Review)
• Copyright: © 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Chemical References

• Amyloid
• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Amyloid (analysis)
• Biological Transport
• Brain (diagnostic imaging)
• Dementia (diagnostic imaging)
• Drug Approval
• Fluorodeoxyglucose F18 (administration & dosage, chemistry, pharmacokinetics)
• Guidelines as Topic
• Humans
• Positron Emission Tomography Computed Tomography (standards)
• Radiopharmaceuticals (administration & dosage, chemistry, pharmacokinetics)
• United States
• United States Food and Drug Administration